Perpetual Medicines Completes $8 Million Seed Round to Advance Integrated Computational Design-Synthesis Platform for Peptide Drug Discovery
Summary
SHANGHAI & BOSTON, December 01, 2023--(BUSINESS WIRE)--Perpetual Medicines today announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery. "Perpetual has assembled a highly experienced senior management team, who have collectively accrued more than 120 years of drug hunting experience and have helped lead the development of more than ten marketed peptide-based therapeutics.The senior management team includes:Kerry L. Blanchard, MD, PhD Co-Founder, Chairman and Chief Executive Officer. He was instrumental in the discovery of four marketed products, oversaw the clinical development and approval of more than 25 new medicines in China, and led two successful IPOs on the Hong Kong stock exchange. The companys platform combines the predictive power of leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access vast, unexplored peptide chemical space. The platform is designed to address previously undruggable targets, accelerate discovery and enhance the quality of peptide drug candidates.